CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 30 enrolled
Drug / intervention
WST11 mediated vascular targeted phototherapy (VTP) +1 moredrug
Likely dose
WST11 mediated vascular targeted phototherapy (VTP) 4 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03617003
NCT03617003Phase 1Completed

Phase I Study of WST11 Phototherapy for Upper Tract Urothelial Carcinoma

Memorial Sloan Kettering Cancer Center·interventional·Posted Aug 6, 2018·Updated Jul 18, 2025

In Brief

A Phase 1 clinical trial evaluating WST11 mediated vascular targeted phototherapy (VTP) and Endoscopy for Upper Tract Urothelial Carcinoma. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to test the safety of a combination of the study drug called WST11 and PDT. Photodynamic therapy (PDT) is a type of ablation therapy (treatment which destroys tumor cells) which has been previously approved for the treatment of patients with other cancers. It works by using a drug that is given through the vein and then is activated in the tumor by light administered during endoscopy, which results in destruction of the cancer cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedAug 6, 2018
Enrollment StartAug 1, 2018
Primary CompletionJul 15, 2025
TodayJul 2, 2026
Enrollment to primary: 7.0 yearsPosted 7.9 years ago

Interventions

WST11 mediated vascular targeted phototherapy (VTP)drug

All patients will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes while patients are under anesthesia during their endoscopy procedure, followed by immediate laser light application.

Endoscopyprocedure

Endoscopy of the bladder